Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.3 USD | -2.13% | -4.56% | +29.94% |
Financials (USD)
Sales 2024 * | 9.22M | Sales 2025 * | 5.09M | Capitalization | 430M |
---|---|---|---|---|---|
Net income 2024 * | -77M | Net income 2025 * | -92M | EV / Sales 2024 * | 35.6 x |
Net cash position 2024 * | 102M | Net cash position 2025 * | 144M | EV / Sales 2025 * | 56.3 x |
P/E ratio 2024 * |
-5.67
x | P/E ratio 2025 * |
-4.84
x | Employees | 52 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 75.23% |
Latest transcript on Taysha Gene Therapies, Inc.
1 day | -2.13% | ||
1 week | -4.56% | ||
Current month | -19.86% | ||
1 month | -24.84% | ||
3 months | +56.46% | ||
6 months | -9.09% | ||
Current year | +29.94% |
Managers | Title | Age | Since |
---|---|---|---|
Sean Nolan
CEO | Chief Executive Officer | 56 | 20-02-29 |
Kamran Alam
DFI | Director of Finance/CFO | 46 | 20-07-31 |
President | 58 | 20-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Philip Donenberg
BRD | Director/Board Member | 63 | 20-08-30 |
Sean Nolan
CEO | Chief Executive Officer | 56 | 20-02-29 |
Sean Stalfort
BRD | Director/Board Member | 54 | 23-06-20 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 2.3 | -2.13% | 1,560,849 |
24-04-24 | 2.35 | -7.11% | 794,093 |
24-04-23 | 2.53 | +2.85% | 1,459,037 |
24-04-22 | 2.46 | +8.37% | 1,459,716 |
24-04-19 | 2.27 | -5.81% | 1,790,537 |
Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+29.94% | 430M | |
+1.12% | 42.59B | |
+6.77% | 40.65B | |
+45.26% | 40.57B | |
-11.96% | 26.77B | |
+6.01% | 24.81B | |
-24.92% | 18.17B | |
-3.63% | 11.7B | |
+27.16% | 12.05B | |
+7.30% | 11.1B |
- Stock Market
- Equities
- TSHA Stock